# A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

Source: https://onco.cc/trials/nct05934331/  
OnCo record `nct05934331` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of LM-302, Toripalimab, Capecitabine, Nivolumab, Rivoceranib (apatinib) and Gemcitabine in advanced solid tumours, run by LaNova Medicines Zhejiang Co., Ltd., now recruiting.

## Summary

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study is a phase 2 interventional study registered as NCT05934331 by LaNova Medicines Zhejiang Co., Ltd., with 276 participants planned, started 2023-07-27 and due to reach its primary completion in 2026-07-01. Interventions recorded: LM-302, Toripalimab, Capecitabine, Tegafur, Gimeracil and Oteracil Potassium Capsules, Nivolumab and Apatinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05934331
- Phase: 2
- Setting: An Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of the LM-302 Combination With Other Anti-tumor Treatment in Subjects With CLDN18.2-positive Advanced Gastro-Intestinal Cancer.
- Sponsor: LaNova Medicines Zhejiang Co., Ltd.
- Enrolled: 276

## Sources

- ClinicalTrials.gov NCT05934331: https://clinicaltrials.gov/study/NCT05934331

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [LM-302](https://onco.cc/drugs/lm-302/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Rivoceranib (apatinib)](https://onco.cc/drugs/rivoceranib/), [Toripalimab](https://onco.cc/drugs/toripalimab/)

---
JSON: https://onco.cc/api/v1/entities/nct05934331.json